Brensocatib, poised for its first FDA decision in non-cystic fibrosis bronchiectasis, shows clear clinical benefits but faces major U.S. market access challenges. We examine Phase 3 ASPEN trial results, safety profile, lack of significant QoL improvements, lingering uncertainty, and ICER’s $7.5M/QALY cost-effectiveness estimate — explaining why MARA Rating’s B++ assessment flags pricing as the key barrier to patient access.

The FDA decision on brensocatib is expected on August 12, 2025 (Priority Review/PDUFA). If approved, it would be the first therapy for non‑cystic fibrosis bronchiectasis. Insmed Incorporated Investor Relations+1

Phase 3 (ASPEN) showed a 19–21% reduction in annualized pulmonary exacerbation rates at 52 weeks; safety was generally favorable with AEs similar to placebo (notably more hyperkeratosis). Chest JournalNew England Journal of MedicineHCP Live

But economics are the gatekeeper. ICER’s draft report—using a placeholder $82,000/yr price from the company’s presentation—finds an incremental cost of roughly $7.5M per QALY; at that price, only ~3% of eligible U.S. patients could be treated over five years before crossing ICER’s $880M/year potential budget impact threshold. ICER

MARA view: our internal, independent MARA Rating is B++—clinical promise is evident, but market access is not assured unless pricing is reviewed (proprietary assessment).

Bottom line: regulatory science may open the door; pricing and reimbursement will decide how many patients walk through it.

Explore our independent assessments: https://mararating.com/mara-ratings-list

Follow MARA Rating for more independent HTA insights: linkedin.com/company/mara-rating-company